Augmentations and rulings of Legendrian knots von Leverson, C.

Volltext

SEMI-LOCAL FORMAL FIBERS OF MINIMAL PRIME IDEALS OF EXCELLENT REDUCED LOCAL RINGS von ARNOSTI, N., KARPMAN, R., LEVERSON, C., LEVINSON, J., LOEPP, S.

Volltext

Augmentations and Rulings of Legendrian Knots von Leverson, C

Volltext bestellen

Augmentations and Rulings of Legendrian Knots von Leverson, C

Volltext

In the Court of Queen's Bench, appeal side George B. C. Leverson & al., plaintifs in the court below, appellants, and James Cunningham, defendant in the court below, and John Bosto... von Leverson, George B. C

Volltext bestellen

Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy von Pan, Rongqing, Ruvolo, Vivian, Mu, Hong, Leverson, Joel D., Nichols, Gwen, Reed, John C., Konopleva, Marina, Andreeff, Michael

Volltext

5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis von Jin, Sha, Cojocari, Dan, Purkal, Julie J, Popovic, Relja, Talaty, Nari N, Xiao, Yu, Solomon, Larry R, Boghaert, Erwin R, Leverson, Joel D, Phillips, Darren C

Volltext

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma von Touzeau, C, Dousset, C, Le Gouill, S, Sampath, D, Leverson, J D, Souers, A J, Maïga, S, Béné, M C, Moreau, P, Pellat-Deceunynck, C, Amiot, M

Volltext

Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM von Moreau, Philippe, Chanan-Khan, Asher, Roberts, Andrew W., Agarwal, Amit B., Facon, Thierry, Kumar, Shaji, Touzeau, Cyrille, Punnoose, Elizabeth A., Cordero, Jaclyn, Munasinghe, Wijith, Jia, Jia, Salem, Ahmed Hamed, Freise, Kevin J., Leverson, Joel D., Enschede, Sari Heitner, Ross, Jeremy A., Maciag, Paulo C., Verdugo, Maria, Harrison, Simon J.

Volltext

Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models von Punnoose, Elizabeth A, Leverson, Joel D, Peale, Franklin, Boghaert, Erwin R, Belmont, Lisa D, Tan, Nguyen, Young, Amy, Mitten, Michael, Ingalla, Ellen, Darbonne, Walter C, Oleksijew, Anatol, Tapang, Paul, Yue, Peng, Oeh, Jason, Lee, Leslie, Maiga, Sophie, Fairbrother, Wayne J, Amiot, Martine, Souers, Andrew J, Sampath, Deepak

Volltext

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets von Souers, Andrew J, Leverson, Joel D, Boghaert, Erwin R, Ackler, Scott L, Catron, Nathaniel D, Chen, Jun, Dayton, Brian D, Ding, Hong, Enschede, Sari H, Fairbrother, Wayne J, Huang, David C S, Hymowitz, Sarah G, Jin, Sha, Khaw, Seong Lin, Kovar, Peter J, Lam, Lloyd T, Lee, Jackie, Maecker, Heather L, Marsh, Kennan C, Mason, Kylie D, Mitten, Michael J, Nimmer, Paul M, Oleksijew, Anatol, Park, Chang H, Park, Cheol-Min, Phillips, Darren C, Roberts, Andrew W, Sampath, Deepak, Seymour, John F, Smith, Morey L, Sullivan, Gerard M, Tahir, Stephen K, Tse, Chris, Wendt, Michael D, Xiao, Yu, Xue, John C, Zhang, Haichao, Humerickhouse, Rod A, Rosenberg, Saul H, Elmore, Steven W

Volltext

Clearance of therapy‐induced senescent tumor cells by the senolytic ABT‐263 via interference with BCL‐XL–BAX interaction von Saleh, Tareq, Carpenter, Valerie J., Tyutyunyk‐Massey, Liliya, Murray, Graeme, Leverson, Joel D., Souers, Andrew J., Alotaibi, Moureq R., Faber, Anthony C., Reed, Jason, Harada, Hisashi, Gewirtz, David A.

Volltext

Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years von Randle, Reese W., MD, Balentine, Courtney J., MD, MPH, Leverson, Glen E., PhD, Havlena, Jeffrey A., MS, Sippel, Rebecca S., MD, Schneider, David F., MD, MS, Pitt, Susan C., MD, MPHS

Volltext

Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma von Kumar, Shaji, Kaufman, Jonathan L., Gasparetto, Cristina, Mikhael, Joseph, Vij, Ravi, Pegourie, Brigitte, Benboubker, Lofti, Facon, Thierry, Amiot, Martine, Moreau, Philippe, Punnoose, Elizabeth A., Alzate, Stefanie, Dunbar, Martin, Xu, Tu, Agarwal, Suresh K., Enschede, Sari Heitner, Leverson, Joel D., Ross, Jeremy A., Maciag, Paulo C., Verdugo, Maria, Touzeau, Cyrille

Volltext

The Tyrosine Kinase Negative Regulator c-Cbl as a RING-Type, E2-Dependent Ubiquitin-Protein Ligase von Claudio A. P. Joazeiro, Wing, Simon S., Huang, Han-kuei, Leverson, Joel D., Hunter, Tony, Liu, Yun-Cai

Volltext

Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models von Han, Lina, Zhang, Qi, Dail, Monique, Shi, Ce, Cavazos, Antonio, Ruvolo, Vivian R, Zhao, Yang, Kim, Eugene, Rahmani, Mohamed, Mak, Duncan H, Jin, Sha S, Chen, Jun, Phillips, Darren C, Koller, Paul Bottecelli, Jacamo, Rodrigo, Burks, Jared K, DiNardo, Courtney, Daver, Naval, Jabbour, Elias, Wang, Jing, Kantarjian, Hagop M, Andreeff, Michael, Grant, Steven, Leverson, Joel D, Sampath, Deepak, Konopleva, Marina

Volltext

MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor von Xiao, Yu, Nimmer, Paul, Sheppard, George S, Bruncko, Milan, Hessler, Paul, Lu, Xin, Roberts-Rapp, Lisa, Pappano, William N, Elmore, Steven W, Souers, Andrew J, Leverson, Joel D, Phillips, Darren C

Volltext

Functional analysis of human microtubule-based motor proteins, the kinesins and dyneins, in mitosis/cytokinesis using RNA interference von Zhu, Changjun, Zhao, Jian, Bibikova, Marina, Leverson, Joel D, Bossy-Wetzel, Ella, Fan, Jian-Bing, Abraham, Robert T, Jiang, Wei

Volltext

Increased synthesis of MCL-1 protein underlies initial survival of EGFR mutant lung cancer to EGFR inhibitors and provides a novel drug target von Song, Kyung-A, Hosono, Yasuyuki, Turner, Crystal, Jacob, Sheeba, Lochmann, Timothy L, Murakami, Yoshiko, Patel, Neha U, Ham, Jungoh, Hu, Bin, Powell, Krista M, Coon, Colin M, Windle, Brad, Oya, Yuko, Koblinski, Jennifer E, Harada, Hisashi, Leverson, Joel D, Souers, Andrew J, Hata, Aaron N, Boikos, Sosipatros A, Yatabe, Yasushi, Ebi, Hiromichi, Faber, Anthony C

Volltext

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax) von Leverson, J D, Zhang, H, Chen, J, Tahir, S K, Phillips, D C, Xue, J, Nimmer, P, Jin, S, Smith, M, Xiao, Y, Kovar, P, Tanaka, A, Bruncko, M, Sheppard, G S, Wang, L, Gierke, S, Kategaya, L, Anderson, D J, Wong, C, Eastham-Anderson, J, Ludlam, M J C, Sampath, D, Fairbrother, W J, Wertz, I, Rosenberg, S H, Tse, C, Elmore, S W, Souers, A J

Volltext